🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the effort against drug-resistant strains of the pathogen, according to researchers.

A Global Challenge

The sexually transmitted infection are escalating globally, with figures suggesting over 82 million infections annually. Especially elevated rates are reported in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune step in the face of rising global incidence, escalating drug resistance and the extremely scarce treatment choices at this time.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Approval

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to develop it.

“This milestone marks a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Testing Results and Worldwide Availability

According to results detailed in a major medical journal, zoliflodacin successfully treated the vast majority of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which uses a dual-drug approach. The research included hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals treating patients have shared hope. Access to a easy-to-administer therapy of this kind is hailed as a "game-changer" for public health efforts. This is considered crucial to lessen the impact of the disease for people and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.